Initially developed for type 2 diabetes, these drugs are now widely used for obesity and cardiovascular risk reduction, with emerging applications in neurological disease [2, 3]
This restriction exists because manufacturer copay assistance programs are structured to reduce patient cost-sharing under insurance plans, not to subsidise retail pricing for cash customers
BioWorld Analysis and data insight Diabetes Endocrine/metabolic Obesity Generic Peptide U.S
This article outlines the place of GLP-1 and GIP analogues in wider therapy, while also highlighting relevant cautions, contraindications and side effects, with the aim of supporting safe prescribing and use of GLP-1 and GIP analogues for glycaemic control in adults with T2DM
Glucagon-like peptide-1 protects beta cells from cytokine-induced apoptosis and necrosis: role of protein kinase B
3 Approximately 50% to 70% of patients also develop Koplik spots, which are small white or grey papules in the mouth, during the prodrome phase